These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. Sanz MA, López J, Lahuerta JJ, Rovira M, Batlle M, Pérez C, Vázquez L, Julià A, Palau J, Gutiérrez M, Capote FJ, Ramos F, Benlloch L, Larrea L, Jarque I, Spanish PETHEMA Group. J Antimicrob Chemother; 2002 Jul; 50(1):79-88. PubMed ID: 12096010 [Abstract] [Full Text] [Related]
5. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Aksoylar S, Cetingül N, Kantar M, Karapinar D, Kavakli K, Kansoy S. Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510 [Abstract] [Full Text] [Related]
6. [Treatment of febrile neutropenia episodes in children, with a piperacillin-tazobactam and netilmicin combination]. Fouyssac F, Salmon A, Mansuy L, Schmitt C, Bordigoni P, Chastagner P. Med Mal Infect; 2005 Jun; 35(6):357-62. PubMed ID: 15982848 [Abstract] [Full Text] [Related]
7. Piperacillin-tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies. Hazel DL, Graham J, Dickinson JP, Newland AC, Kelsey SM. J Chemother; 1997 Aug; 9(4):267-72. PubMed ID: 9269607 [Abstract] [Full Text] [Related]
12. Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. Cornely OA, Wicke T, Seifert H, Bethe U, Schwonzen M, Reichert D, Ullmann AJ, Karthaus M, Breuer K, Salzberger B, Diehl V, Fätkenheuer G. Int J Hematol; 2004 Jan; 79(1):74-8. PubMed ID: 14979482 [Abstract] [Full Text] [Related]
13. Piperacillin/tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients with haematological malignancy. Kelsey SM, Weinhardt B, Pocock CE, Shaw E, Newland AC. J Chemother; 1992 Oct; 4(5):281-5. PubMed ID: 1336043 [Abstract] [Full Text] [Related]
17. Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients. Micozzi A, Nucci M, Venditti M, Gentile G, Girmenia C, Meloni G, Martino P. Eur J Clin Microbiol Infect Dis; 1993 Jan; 12(1):1-8. PubMed ID: 8385015 [Abstract] [Full Text] [Related]
18. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Hess U, Böhme C, Rey K, Senn HJ. Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210 [Abstract] [Full Text] [Related]
19. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Böhme A, Shah PM, Stille W, Hoelzer D. Eur J Med Res; 1998 Jul 20; 3(7):324-30. PubMed ID: 9682028 [Abstract] [Full Text] [Related]
20. A clinical evaluation of efficacy and safety of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia in a tertiary care centre of north India. Aamir M, Abrol P, Sharma D, Punia H. Trop Doct; 2016 Jul 20; 46(3):142-8. PubMed ID: 26612093 [Abstract] [Full Text] [Related] Page: [Next] [New Search]